Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Johnson & Johnson Completes Tender Offer for Mentor Corporation Jan 23, 2009 |
6.5 KB |
|
|
NEW BRUNSWICK, N.J., Jan 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the expiration of the subsequent offering period of the cash tender offer through its wholly owned subsidiary, Maple Merger Sub, Inc., for all outstanding shares of common stock of Mentor Corporation (NYSE: MNT). The su... |
|||
|
NEW BIOLOGIC STELARA™ RECEIVES APPROVAL IN EUROPE FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS Jan 22, 2009 |
9.7 KB |
|
|
BEERSE, BELGIUM, 22 January, Janssen-Cilag announced today that STELARA™ (ustekinumab), the first in a new class of biologics, has been approved by the European Commission for use across Europe. The approved indication of ustekinumab is for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a ... |
|||
|
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results Jan 20, 2009 |
41.2 KB |
|
|
NEW BRUNSWICK, N.J., Jan 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- 2008 Full-Year Sales of $63.7 Billion increased 4.3%; Full-Year EPS was $4.57 2008 Fourth-Quarter Sales of $15.2 Billion decreased 4.9%; EPS was $0.97 Excluding Special Items, 2008 Full-Year EPS was $4.55, an increase of 9.6% and Fourth-Quarter EPS was $0.94, an i... |
|||
|
Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered Jan 17, 2009 |
8.7 KB |
|
|
NEW BRUNSWICK, N.J., Jan 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- - Johnson & Johnson Will Commence Subsequent Offering Period Johnson & Johnson (NYSE: JNJ) today announced that the initial tender offer, through its wholly owned subsidiary, Maple Merger Sub, Inc., for all outstanding shares of common stock of Mentor Corporation (... |
|||
|
Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation Jan 15, 2009 |
7.8 KB |
|
|
NEW BRUNSWICK, N.J., Jan 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that all applicable foreign antitrust and similar regulatory clearances required for its cash tender offer to purchase all outstanding shares of common stock of Mentor Corporation (NYSE: MNT) were obtained, or the releva... |
|||
|
Court of Appeals Overturns 2005 Patent Verdict Against Cordis Jan 15, 2009 |
6.0 KB |
|
|
WARREN, N.J., Jan 15, 2009 /PRNewswire via COMTEX News Network/ -- The Court of Appeals for the Federal Circuit in Washington, D.C. today found Boston Scientific Corporation's Ding patent invalid, and reversed a 2005 jury finding that Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent infringed that patent. Cordis is very pleased with... |
|||
|
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2008 Financial Results Jan 13, 2009 |
6.1 KB |
|
|
NEW BRUNSWICK, N.J., Jan 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 20, 2009, to discuss fourth-quarter and full-year 2008 financial results. The meeting will be hosted by William C. Weldon, Chairman and Chief Executive Officer. Investors a... |
|||
|
Johnson & Johnson Extends Tender Offer for Mentor Corporation Jan 6, 2009 |
7.7 KB |
|
|
NEW BRUNSWICK, N.J., Jan 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced it has extended its previously announced cash tender offer, through its wholly owned subsidiary, Maple Merger Sub, Inc., for all outstanding shares of common stock of Mentor Corporation (NYSE: MNT) until 5:00 p.m. (Easte... |
|||
|
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc. Dec 30, 2008 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., Dec 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. Omrix is expected ... |
|||
|
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc. Dec 27, 2008 |
6.3 KB |
|
|
NEW BRUNSWICK, N.J., Dec 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that stockholders of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) ("Omrix") tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedu... |
|||
|
VITROS® 3600 Immunodiagnostic System for Laboratory Diagnostics Receives 510(K) Clearance from the FDA Dec 23, 2008 |
11.6 KB |
|
|
RARITAN, N.J. (December 23, 2008) - Ortho Clinical Diagnostics today announced 510(k) clearance from the United States Food and Drug Administration (U.S. FDA) for its VITROS® 3600 Immunodiagnostic System. This new high-capacity immunoassay system provides laboratories with a truly innovative solution to ad... |
|||
|
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc. Dec 19, 2008 |
7.6 KB |
|
|
NEW BRUNSWICK, N.J., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Binder Merger Sub, Inc., for all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) until ... |
|||
|
Johnson & Johnson Strengthens Wellness & Prevention Platform with Acquisition of Human Performance Institute(TM) Dec 19, 2008 |
7.3 KB |
|
|
NEW BRUNSWICK, N.J., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Extending its capabilities in wellness and prevention, Johnson & Johnson (NYSE: JNJ) announced today it has acquired LGE Performance Systems, Inc., a privately held company located in Orlando, Florida, known as Human Performance Institute. Human Performance Institut... |
|||
|
FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application Dec 19, 2008 |
9.6 KB |
|
|
HORSHAM, PA, December 19, 2008 - Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab. The application, filed by Centocor in late 2007, seeks approval to market ustekinumab as a subcutaneous biologic therapy for the tr... |
|||
|
ETHICON Launches the Latest Innovation in Hernia Repair Platform Dec 16, 2008 |
6.9 KB |
|
|
Somerville, NJ (December 16, 2008) - ETHICON, INC, a global medical device company, today announced the launch of the PROCEED Ventral Patch (PVP Device), the latest addition to its family of hernia products. PVP Device is the first and only umbilical hernia repair device featuring lighter-weight mesh and exclusive, absorbable deployment technolo... |
|||
|
Approval of STELARATM in Canada Marks Advancement in Treatment of Moderate to Severe Plaque Psoriasis Dec 15, 2008 |
13.0 KB |
|
|
Toronto, ON - (December 15, 2008) - Canadians living with moderate to severe plaque psoriasis, a chronic and often debilitating inflammatory disease, now have a new treatment option with the approval of STELARA™(ustekinumab). STELARA, which is self-injected every 12 weeks following two starter doses at weeks 0 and 4, has ... |
|||
|
Study Finds DOXIL® Combination Therapy Delays Disease Progression for Patients with Metastatic Breast Cancer Dec 14, 2008 |
17.2 KB |
|
|
Study Finds DOXIL® Combination Therapy Delays Disease Progression for Patients with Metastatic Breast CancerSan Antonio, TX (December 14, 2008) – Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time t... |
|||
|
Johnson & Johnson Begins Tender Offer to Acquire Mentor Corporation Dec 12, 2008 |
7.6 KB |
|
|
NEW BRUNSWICK, N.J., Dec 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) is commencing today, through a new wholly owned subsidiary, Maple Merger, Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Mentor Corporation (NYSE: MNT). Johnson & Johnson reported on December 1, 200... |
|||
|
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix Dec 11, 2008 |
7.4 KB |
|
|
NEW BRUNSWICK, N.J., Dec 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that the Israeli General Director of the Antitrust Authority has approved Johnson & Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI), under the Restrictive Trade Practices Law 5748-1988 of ... |
|||
|
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia Dec 9, 2008 |
68.5 KB |
|
|
Titusville, NJ, December 9, 2008 - Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today.1 Statistical significance was evidenced at all doses tested (25, 100, an... |
|||
= add release to Briefcase
